Wound-Healing in the Saphenous Vein Coronary Bypass Graft in the Canine Model: Endothelial Cell Loss, Platelet Thrombus Formation, its Inhibition with Aspirin-Persantine Therapy and Cholesterol Influx in the Acute and Chronic Phase

Mrinal K. Dewanjee*

Neurobiology, Neurodegeneration & Retina Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, USA

Abstract

Radiolabeling of the platelets with Indium-111 tropolone and the LDL-C and HDL-C lipoproteins with Iodine-131 and Iodine-125 provided us a with a quantitative method of measurement of platelet deposition and uptake of Iodine-131 and C-14 labeled cholesterol, LDL-C and HDL-C on all segments of coronary artery bypass graft in the acute and chronic phase in the canine model. We sampled the thrombogenicity and cholesterol uptake for a 24-hours exposure/interaction time of tracers after intravenous injection, post-CABG implantation at 1, 3, 7, 30, 90 and 365 days. Most of the reactivities of components of CABG or components of cardiovascular prostheses are passivated after absorption of albumin, and coverage with fibroblasts and/or partially with endothelial cells. Although we calculated the percent of injected dose on CABG segments, the algebraic equation for the calculation of Regional Platelet Density (RPD) revolutionized our measurement methods. RPD was higher at the proximal and distal anastomoses than the mid-section of CABG.

Introduction

After I joined Mayo Clinic as a staff consultant and Director of Radioactive Drug Laboratory in Nuclear Medicine Division, I had a surprise visit from a young cardiologist, Dr. Valentin Fuster. Valentin congratulated me for my synthesis of Technetium-99m tetracyclines and their evaluation in the “Dead Cell model” and noninvasive imaging of myocardial infarct in canine model and Boston patients [1-3]. Valentin mentioned that there is no such method available for the measurement of platelet thrombus in the coronary artery-the culprit for inducing MI. He offered me his million-dollar grant, if I wanted to work on the thrombus imaging and measurements. In mid-1970, (25-30) % of distal anastomosis of CABG was occluded with limited choice for the patients for recuperation with another vessel. We wanted to maintain CABG patency in the canine model with dual platelet-inhibitors: aspirin post CABG and Persantine, before surgery.

After three years of measurements using radioactivity ratios of control saphenous vein and CABG segments and percent of injected dose, I wanted to quantify the regional platelet density, a universal and an absolute parameter for the measurement of thrombogenicity in 1979 and made the simple Algebraic equation [4-7] from three unknown variable parameters and three equations. I also kept my promise to my visiting mother from Kolkata, India, to solve the thrombus puzzle and use minimal number of cows for evaluation of the calcification of platelet thrombus in the tissue heart valves [8-15]. Last year, 2019, was the 40th anniversary and I decided to write a comprehensive book on the number one killer, measuring and imaging the platelet thrombi and emboli [16]. With the assistance from Dr. JS Robertson, we did the estimate of human dosimetry study [17,18].
and I wrote an IND to FDA for clinical investigations on the thrombogenicity of synthetic vascular grafts [13,19-22] and mechanical heart valves and the effect of multiple platelet-inhibitors, used today in clinical practice.

Since the original clinical study in 1968 by Dr. Rene Favaloro at Cleveland Clinic, the saphenous vein Coronary Artery Bypass Graft (CABG) provides a unique conduit for a second chance of coronary circulation [23] after diffuse plaque occlusion and myocardial infarction. Unlike the focal occlusion, where the angioplasty followed by stenting played a predominant role, for the patients suffering from the multivessel diffuse coronary occlusions, CABG is now perfected and is an acceptable procedure with low risk of bleeding, thrombosis and infection [9]. I summarized the critical steps of rapid interventions by the radiologists or cardiologists as dictated by the 5-hour narrow window of myocardial preservation after coronary plaque rupture that results in coronary occlusion or focal occlusion and their recanalization by angioplasty/stenting or CABG for multi-vessel diffuse occlusions (Figure 1).

The cardiopulmonary bypass procedure perturbs the platelet-kinetics and thrombosis on CABG segments. We carried out separate control experiments on the status of platelet consumption and thrombus formation on the components of the heart-lung machine [14,15,19,24-30]. In addition, the hollow-fiber oxygenator also induces platelet fragmentation reducing their potential for additional thrombus formation. However, as new generation of platelets pour out of the bone marrow, these activated platelets form thrombi on all surfaces of major vessels and the sites of thoracic incisions. We also estimated that ~15-20% of platelets were consumed by the wound surfaces of major vessels and the sites of thoracic incisions. After 24 hours, the dogs were heparinized and euthanized [31-36].

Radioiodination of canine LDL-C with I-131 and LDL-C with I-125 radionuclide using the IodoGen transfer method

Canine LDL-C and HDL-C particles were separated using the cesium-chloride density-gradient method with an ultracentrifuge (Beckman, Inc.). Stock solutions separated lipoproteins were radiolabeled in a chemical hood using the IodoGen-transfer method and the free radiodide was separated from radiolabeled lipoproteins by gel-filtration. They were filtered for sterilization and aliquots were kept frozen. After thawing and filtering to remove sediments, they were injected intravenously with C-14 and I-131 tagged cholesterol along with radiodiode-tagged lipoproteins after the CABG procedure. After 24 hours, the dogs were heparinized and euthanized [31-36].

Figure 1: Translation research-infarct imaging.

Figure 2: Platelet labeling with the charge-neutral and water soluble In-111 tropolone complex and the optimal method of platelet labeling in ACD-saline or ACD-plasma media. Only purified platelet fraction separated from other cells in whole blood must be incubated with In-tropolone complex.

Methods

Aortocoronary bypass grafting in the canine model

An autologous segment of reversed femoral vein was implanted as a bypass-graft from the aorta to the left anterior descending coronary artery in 50 mongrel dogs weighing 18 to 26 kg, using the cardiopulmonary bypass procedure [6,24].

Oral medication with diprydamole and aspirin

25 dogs were used as control and they were treated only with systemic antibiotics during surgery (Untreated group); the other 25 were given diprydamole, 55 mg orally, on 2 days preceding surgery and then were given 55 mg of diprydamole and 325 mg of aspirin at 1 hr after surgery and daily thereafter until they were euthanized with Nembutal.

Autologous platelet labeling with indium-111 tropolone

Autologous platelets of the dogs were labeled with In-111 (tropolone) 3 according to the method of Dewanjee et al., and injected intravenously with 300-400 microcuries [4-6]. The platelet-rich plasma was separated from blood anticoagulated with acid citrate dextrose solution and ACD-saline washed platelets were labeled with the procedure as shown in figure 2.
The CABG segments were cut into five segments, weighed and radioactivity was measured in a calibrated gamma-ray spectrometer (Beckman, Inc.). Control saphenous vein were isolated and radioactivity per unit weight was calculated. The ratio of CABG segments was compared to that of control radioactivity. Unlike In-111 tagged platelets, where anastomoses retained higher level of radioactivity, the distribution of I-125 and I-131 tagged lipoproteins on CABG segments were uniform. We plotted the radioactivity ratios of CABG segments to control vein during (Figures 3 and 4) our follow-up period of 1-365 days post CABG [32].

Figure 3: Chronological SEM evaluation to correlate the changes of endothelial loss in the saphenous vein segments of CABG and platelet aggregates from day 1 to and 7 days after grafting and reendothelialization at 30 and 90 days.

Figure 4: Rapid uniform deposition of iodine-131 and C-14 labeled cholesterol, HDL-C and LD-CL on CABG segments from EC-loss with respect to control saphenous vein graft at 24 hours after IV injection. Statin therapy is essential after CABG due to patchy EC loss and rapid cholesterol, LDL-C and HDL-C influx.

Figure 5: Chronological quantitation of the Regional Platelet Density (RPD: Platelets/cm²), an absolute value derived from the segment-adherent platelet radioactivity in the thrombus from day1 to day 90, highest RPD was always at the proximal and distal anastomoses than the mid-section of CABG. After EC-coverage, there is no difference in RPD value.

Figure 5 the coronary artery bypass graft model (A). The saphenous vein was harvested and anastomosed to aorta at the proximal end and to coronary artery at the distal end (likely site of occlusion) beyond the ligated site. For mapping the adherent regional thrombi, the graft was carefully dissected from the heparinized and euthanized dog. It was cut into five segments and surface area was measured by placing them on a graph paper. Platelet density was calculated from the Dewanjee equation (B). Level of thrombi was highest at both anastomoses and lower in the midsection of graft [30]. However, the platelet density decreased in both control and Aspirin-Persantine treated groups always lower in the treated group. During harvesting, patchy areas of vein graft loses endothelial cells as shown by the SEM study. As the patches of injured vein-wall were re-endothelialized, there was no difference of platelet density at 90 days (D). Initially, we also compared radioactivity of the walls of CABG graft and control artery or vein (C). This the first study of long-term follow-up of CABG thrombi and their sequential reduction as the wound-healing progresses on graft intimal surface with and without platelet-inhibitors. Dr. Rene Favaloro, the first surgeon of Argentine, who did the CABG surgery at Cleveland Clinic on November 30, 1967, will be delighted at the high acceptance level of his life-saving intervention all over the world.

Figure 3 SEM of gold-coated CABG segments at day 1, 7, 30 and 90 (Left). Note complete Endothelial Cell (EC) coverage of CABG at day 90. Platelet agonist-induced aggregation (Right). Was reduced was minimized with Aspirin-Persantine administration. After complete EC coverage, no drugs were necessary [10].

Consumption of platelets for surgical repair and wound-healing, Interaction time of blood-device interactions for in vitro and animal studies

Most of the clinicians and surgeons do not have access to data about many issues related to complex cardiovascular surgery, e.g. how much platelets are consumed for Surgical Repair and Wound Healing (SRWH). What biomaterials are less thrombogenic for making a functional device? What is the right dose and when they must be administered not to enhance bleeding complications? Open-heart surgery alone with a heart-lung machine makes it difficult to sort out the issues of surgery vs.

Prosthesis we limited the post-clamping surgical time or hemodiagnosis time to 90-180 minutes in three animal models in dogs, cows and cows [6,14,24,26]. We also measured the platelet emboli in the cortex of brain and kidneys by measuring the tissue/blood radioactivity ratios. They increased twofold to fourfold after implantation of the mechanical heart valve in the canine model [5,8]. By injecting In-111 tagged platelets before and after this surgery, we measured that (15-20) % of total platelets are consumed for SRWH in the canine model, which are not easily extrapolated to patients due to higher platelet thrombogenicity. In most of the studies, we try to simulate the
Short blood-biomaterial interaction time (less than 24 hours) does not provide reproducible data with acceptable standard deviations [11-13]. We limited the duration of in vitro experiments using the flow-loop to one to three hours [26]. Longer over-night run resulted in the buildup of pressure and rupture of circuit and splashing of radioactive precious human blood! For the patients, we only could gather semi-quantitative platelet-deposition data due to slower clearance of in-111 platelet radioactivity [13,29] except in the splenomegaly patient, which showed of acquisition of platelet pool of 68% in the spleen [37]. Measurements before and after surgery with a calibrated gamma camera provided the best data for the attenuation correction of the 171- and 247-keV gamma-ray photons [17,37].

Kinetics of thrombosis and healing are two to three times faster in the dog model as we studied the platelet reactivity with a hemodialyzer in the flow-loop with both platelet and fibrinogen tracers respectively [5]. Canine platelets are three-times more thrombogenic than human platelets. Porcine platelets are slightly more thrombogenic than human platelets and a lot of other cardiovascular functions and platelet pharmacology is closer to that of human health. However, no such difference was found for the deposition of fibrinogen for all three species we measured. From the I-125 tagged fibrinogen, we could estimate the mixed amount of fibrinogen along with the corresponding fibrin fragments (Figure 6). For the healing of human saphenous vein-coronary bypass graft, it might take four to six months, while it is two-to-three months in the canine model. The vascular surgeons also learned a lesson of vein harvesting in a gentle manner and the preservation in human serum or plasma to preserve the endothelial cells so that graft-healing on all segments would occur, including the wound-healing of complex area of anastomoses could be accelerated.

**Discussion**

Therapeutic mechanisms of aspirin and dipyridamole Aspirin inhibit the formation of the aggregating agents, e.g. prostaglandins G2 and H2 and thromboxane A2 from arachidonic acid, by acetylation of platelet cyclooxygenase. Its inhibition of platelet cyclooxygenase persists about three times longer than the inhibition of endothelial cyclooxygenase. Prostacyclin synthesis by the endothelial cell is less affected by aspirin. The prostacyclin production in the vascular endothelium is compromised by the partial de-endothelialization of the edematous vessel wall. Dipyridamole, an inhibitor of cyclic AMP phosphodiesterase, increases cyclic AMP in platelets and suppresses platelet activation [5,9,13,30,39-41].

**Study methods**

Higher platelet deposition at the anastomotic sites was observed by light microscopic and electron microscopic techniques. However, it is inadequate for the calculation of the number of platelets per unit of surface area. We also estimated that about (20-30)% of the platelets are consumed in the bubble oxygenator and another (15-20)% are consumed in repair of blood vessels [6,24-26]. With the novel design of the hollow-fiber oxygenators, the adherent thrombus decreased to less than 0.25% [25].

Electron microscopic techniques are useful in demonstrating the patchy de-endothelialization and the adherence of single and multi-platelet aggregates to deendothelialized surface. However,
multiple manipulations during specimen preparation, e.g. pressure-perfusion, fixation, gold-coating, resulted in the loss of surface-adherent platelets and underestimated of platelet thrombus. The radioactivity-measurement method is ideal for studying platelet thrombosis in the arterial system as well as for evaluation of platelet-inhibitors in models of bilateral femoral-graft implants [5]. Considering the restrictions on the use of radionuclides in large animals, these procedures will not be repeated [5,7,30] for the clarification of the role of EC loss, platelet thrombus formation, cholesterol buildup and calcification of platelet thrombus.

Since thrombosis with the platelet-fibrin mesh occurs on the injured surface or surfaces of thrombogenic biomaterials, the normalized value of regional platelet density, expressed as number of adherent platelets per unit surface area, is the best method of measurement. We carried out these measurements in a large numbers of animals and more than 200 human subjects implanted with thrombogenic Dacron polyester (polyethylene terephthalate) and GoreTex (Teflon) grafts. The tracer technique is five to 100 times more sensitive [11,14,15,29].

**Clinical implications of the quantitative measurements**

In managing the CABG patients, it is essential to prevent thrombotic graft occlusion without inducing excessive postoperative bleeding. Multiple parameters, e.g. side effects of drugs, variability of intolerance, drug cost and compliance of patients to drug therapy, complicate decisions as to how long the treatment should be continued. Our animal studies suggest a relatively short therapy-period for CABG is necessary. However, their healthy coronary arteries and healthy veins might benefit less from prolonged inhibition of platelet deposition than do the diseased veins and coronary arteries of man [9,28]. In patient pool having an athrogenic diet, adverse lipoprotein profile, rate of slower reendothelialization or recurrent endothelial damage, prolonged platelet-inhibitor therapy is justified. Considering the small lumen at the distal anastomoses, the inhibitors of platelet adhesion must be present in this critical early period [7,32].

The advantage of the tracer technique is that we estimated the total platelet deposition over a wider surface area [5,14,15], whereas the electron microscope reveals only the superficial layer of platelets on a injured surface or surfaces of thrombogenic biomaterials. In addition, we used the platelet swiping method to study the effect of stenotic versus aneurysm configuration without destroying the well-designed plexiglass tube [42].

**Acknowledgements**

I thank Dr. Valentin Fuster and Dr. Michael Kaye for proposing and setting up the CABG study in the canine model. I also thank the Shiley and Baxter staff for supplying the cardiopulmonary bypass circuits and Boehringer-Ingelheim, Inc for supplying the10 kg-stock of Persantine powder. NHLBI support via the HL47201 grant is appreciated.

**References**

1. Holman BL, Iodine J, Fliegel CP, Davis MA, Trevos S, et al. (1973) Detection and localization of experimental myocardial infarction with 99mTc-tetracycline. J Nucl Med 14: 595-599.

2. Dewanjee MK, Prince EW (1974) Cellular necrosis model in tissue culture: uptake of 99m(Tc) tetracycline and the pertechnetate ion. J Nucl Med 5: 577-581.

3. Dewanjee MK (1990) The chemistry of 99mTe-labeled radiopharmaceuticals. Seminars in Nuclear Medicine 20: 5-27.

4. Dewanjee MK, Rao SA, Didisheim P (1981) Indium-111 tropolone, a new high-affinity platelet label: preparation and evaluation of labeling parameters. J Nucl Med 22: 981-987.

5. Dewanjee MK (1987) Methods of assessment of thrombosis in vivo. Ann N Y Acad Sci 516: 541-571.

6. Dewanjee MK, Fuster V, Kaye MP, Josa M (1978) Imaging platelet deposition with 111In-labeled platelets in coronary artery bypass grafts in dogs. Mayo Clin Proc 58: 327-331.

7. Dewanjee MK, Tago M, Josa M, Fuster V, Kaye MP (1984) Quantification of platelet retention in aortocoronary femoral vein bypass graft in dogs treated with dipyridamole and aspirin. Circulation 69: 350-356.

8. Dewanjee MK, Fuster V, Rao SA, Forshaw PL, Kaye MP (1983) Noninvasive radioisotopic technique for detection of platelet deposition in intraluminal protheses and quantitation of visceral microembolism in dogs. Mayo Clin Proc 58: 307-314.

9. Fuster VD, Badimon L, Badimon JJ, Cesebro JH (1992) The pathology of coronary artery disease and acute coronary syndrome. N Engl J Med 326: 242-250.

10. Evrard SM, Leece L, Michelis KC, Nomura-Kitabayashi A, Pandey G, et al. (2016) Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun 7: 11853.

11. Didisheim P, Tirrell MV, Lyons CS, Dewanjee MK (1983) Relative role of surface chemistry and surface texture in blood-material interactions. Trans Am Soc Artif Intern Organs 29: 169-176.

12. Steele PM, Cesebro JH, Stanson AW, Holmes DR, Dewanjee MK, et al. (1985) Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 57: 105-112.

13. Agarwal KC, Wahnner HW, Dewanjee MK, Fuster V, Puga FJ, et al. (1982) Imaging of platelets in right-sided extracardiac conduits in humans. J Nucl Med 23: 342-347.

14. Dewanjee MK, Solis E, Mackey ST, Lenker J, Edwards WD, et al. (1986) Quantification of regional platelet and calcium deposition on pericardial tissue valve prostheses in calves and effect of hydroxyethylene diphosphonate. J Thorac Cardiovasc Surg 92: 337-348.

15. Dewanjee MK (1990) Quantitation of Platelet Thrombus in Cardiac Valve Prostheses with the Radiolabeled Platelets. In: Kessler C. (eds) Platelets and Atherosclerosis. Springer, Berlin, Heidelberg Pg no: 71-86.

16. Dewanjee MK (2020) Measuring and Imaging Platelet Thrombi and Emboli: Saving Patients from Myocardial Infarct and Stroke with Drugs, Devices and Genetics. Submitted to Springer-Nature, January 2020. *On June 5,2019, I made a Grand Rounds Lecture at Lipsett auditorium on a similar topic, 30 years of my lifetime of work in 30 minutes, sharing the podium with another cardiologist at NHLBI, Dr. Manfred Baum.

17. Robertson JS, Dewanjee MK, Brown ML, Fuster V, Cesebro JH (1981) Distribution and dosimetry of 111In-labeled platelets. Radiology 140: 169-176.

18. Robertson JS, Ezekowitz MD, Dewanjee MK, Lötter MG, Watson EE (1992) MIRD dose estimate no. 15: radiation absorbed dose estimates for radioidium-labeled autologous platelets. J Nucl Med 33: 777-780.

19. Pumphrey CW, Fuster V, Dewanjee MK, Murphy KP, Vlietstra RE, et al. (1982) A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs. Thromb Res 28: 663-675.

20. Plate G, Hollier LH, Giovizci P, Dewanjee MK, Kaye MP (1984) Overcoming failure of venous vascular prostheses. Surgery 96: 503-510.
21. Dewanjee MK, Wahner WH, Dunn WL, Robertson JS, Offord KP, et al. (1986) Comparison of three platelet markers for measurement of platelet survival time in healthy volunteers. Mayo Clin Proc 61: 327-336.

22. Dewanjee MK, Solis E, Mackey ST, Lenker J, Edwards WD, et al. (1986) Quantification of regional platelet and calcium deposition on pericardial tissue valve prostheses in calves and effect of hydroxyethylène diphosphonate. J Thorac Cardiovasc Surg 92: 337-348.

23. Favaloro RG (2000) Surgical treatment of acute myocardial infarction. J American College of Cardiology 35: 18-24.

24. Dewanjee MK, Vogel SR, Peterson KA, Lim MF, Kaye MP (1986) Quantitation of platelet lysis, platelet consumption on oxygenator, and stabilization of platelet membrane with prostacyclin and ibuprofen during cardiopulmonary bypass surgery in dogs. Trans Am Soc Artif Intern Organs 27: 197-202.

25. Dewanjee MK, Wu SM, Burke GW, Hsu LC (1998) Tumor necrosis factor-alpha in plasma during cardiopulmonary bypass in a pig model: correlation with marginated neutrophils and cerebral edema by magnetic resonance imaging. ASAIO J 44: 212-218.

26. Dewanjee MK, Belinskiy VV, Holland JF, Kapadvanjwala M, Wu SM, et al. (1996) Effect of Thoracotomy and Cardiopulmonary Bypass on Activated Platelet and Neutrophil Dynamics and Platelet Emboli in a Pig Model. J Thromb Thrombolysis 3: 195-208.

27. Leslie M (2017) Will surgery sap your brain power? Science 356: 898-900.

28. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, et al. (2001) Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 344: 395-402.

29. Lovaas ME, Glocvitzki P, Dewanjee MK, Hollier LH, Kaye MP (1983) Inferior vena cava replacement: the role of antiplatelet therapy. J Surg Res 35:234-242.

30. Dewanjee MK (1992) Radioiodination: Theory, Practice, and Biomedical Applications. Developments in Nuclear Medicine 21: 1-621.

31. Dewanjee MK (1992) Cardiac and vascular imaging with labeled platelets and leukocytes. Sem Nucl Med 14: 154-187.

32. Dewanjee MK, Tago M, Ellefsen RD, et al. (1984) Endothelial permeability and uptake of C-14 cholesterol, I-125-labeled high density- and I-131-low density lipoproteins in aortocoronary femoral vein bypass graft in dogs, in 5th Int Symp Radiopharm Chem, Tokyo, Japan.

33. Ridker PM (2014) LDL cholesterol: controversies and future therapeutic directions. Lancet 384: 607-617.

34. Yurdagul A, Doran AC, Cai B, Fredman G, Tabas IA (2018) Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis. Front Cardiovasc Med 4: 86.

35. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, et al. (2019) Atherosclerosis. Nat Rev Dis Primers 5: 1-56.

36. Dewanjee MK, Pumphrey CW, Murphy KP, Rosemark JA, Chesebro JH, et al. (1982) Evaluation of platelet-inhibitor drugs in a canine bilateral femoral graft implant model. Trans Am Soc Artif Intern Organs 28: 504-509.

37. Virchow R (1856) Phlogose und thrombose in gefassystem, gesamelte abhandlungen zur wissenshaftlichen medicin. Frankfurt-am-Main. Germany: Meidinger Sohn 458.

38. Sun BK, Siprashvili Z, Khavari PA (2014) Advances in skin grafting and treatment of cutaneous wounds. Science 346: 941-944.

39. Third GS, Parida R, Gupta N (2014) Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. Ther Clin Risk Manag 10: 885-900.

40. Solis E, Hollier LH, Plate G, Dewanjee MK, Kaye MP (1986) Early and late comparison of umbilical vein and PTFE grafts in control and piroxicam-treated dogs. Int Angiol 5: 73-78.

41. Cirillo P, Serafino LD, Tagliatela V, Calabrò P, Antonucci E, et al. (2020) Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology 71: 235-241.

42. Schoephoerster RT, Oynes F, Nuñez G, Kapadvanjwala M, Dewanjee MK, et al. (1993) Effects of local geometry and fluid dynamics on regional platelet deposition on artificial surfaces. Arterioscler Thromb 13: 1806-1813.
